Vaxxinity, Inc. (NASDAQ:VAXX) Insider Mei Mei Hu Buys 8,038 Shares

Vaxxinity, Inc. (NASDAQ:VAXXGet Rating) insider Mei Mei Hu purchased 8,038 shares of the stock in a transaction dated Monday, April 25th. The stock was purchased at an average cost of $3.37 per share, for a total transaction of $27,088.06. Following the completion of the acquisition, the insider now owns 51,593,454 shares of the company’s stock, valued at approximately $173,869,939.98. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of Vaxxinity stock opened at $3.61 on Thursday. Vaxxinity, Inc. has a 12-month low of $3.04 and a 12-month high of $22.77. The company has a current ratio of 5.61, a quick ratio of 5.61 and a debt-to-equity ratio of 0.08. The stock has a 50-day moving average price of $4.20.

Vaxxinity (NASDAQ:VAXXGet Rating) last announced its earnings results on Thursday, March 24th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.13). On average, analysts anticipate that Vaxxinity, Inc. will post -1.69 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in VAXX. FNY Investment Advisers LLC purchased a new stake in Vaxxinity in the fourth quarter valued at approximately $27,000. Geode Capital Management LLC purchased a new stake in Vaxxinity in the fourth quarter valued at approximately $382,000. ETF Managers Group LLC purchased a new stake in Vaxxinity in the fourth quarter valued at approximately $211,000. Goldman Sachs Group Inc. purchased a new stake in Vaxxinity in the fourth quarter valued at approximately $1,240,000. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in Vaxxinity in the fourth quarter valued at approximately $5,619,000.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Vaxxinity from a “hold” rating to a “sell” rating in a report on Thursday, April 7th. Evercore ISI assumed coverage on shares of Vaxxinity in a report on Wednesday. They issued an “in-line” rating on the stock.

About Vaxxinity (Get Rating)

Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD.

Recommended Stories

Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.